Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Univo Pharmaceuticals Ltd
  6. News
  7. Summary
    UNVO   IL0010935588

UNIVO PHARMACEUTICALS LTD

(UNVO)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Univo Pharmaceuticals Ltd announced that it expects to receive ILS 5.994553 million in funding from EFGPharm Ltd.

10/30/2019 EST

Univo Pharmaceuticals Ltd (TASE:UNVO) announced that it will issue 1,225,880 shares at issue price of ILS 4.89 per share for gross proceeds of ILS 5,994,553.2 on October 30, 2019. The transaction will include participation from EFGPharm Ltd. The company also issued 500,359 warrants. Each warrant can be exercised to purchase one common share of the company at an exercise price of ILS 4.5 per warrant for a period of 12 months from the closing of the transaction. All the securities issued in the transaction is subject to a hold period of 6 months from the closing of the transaction.


ę S&P Capital IQ 2019
All news about UNIVO PHARMACEUTICALS LTD
08/31Univo Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended June 30, 202..
CI
2020Can-Fite Biopharma Ltd. Announces New Pre-Clinical Findings in Connection with its On-G..
CI
2020Can-Fite Biopharma Ltd and Univo Pharmaceuticals Ltd Collaboration Result in Discovery ..
CI
2019Univo Pharmaceuticals Ltd announced that it expects to receive ILS 5.994553 million in ..
CI
2019Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabin..
CI
2019Univo Pharmaceuticals Ltd announced that it expects to receive ILS 2.499999 million in ..
CI
2019Univo Pharmaceuticals Ltd announced that it has received ILS 3 million in funding
CI
2019UNV Medicine LTD. announced that it has received ILS 6 million in funding from Hagag Gr..
CI
2018UNV-Medicine Signs New Deal with Israeli Cannabis Startup
CI
2018UNV Medicine Ltd. completed the acquisition of D-Pharm LTD. in a reverse merger transac..
CI
More news
Financials
Sales 2019 0,82  0,26  0,26 
Net income 2019 -11,8 M -3,73 M -3,73 M
Net cash 2019 22,8 M 7,22 M 7,22 M
P/E ratio 2019 -5,92x
Yield 2019 -
Capitalization 65,6 M 20,8 M 20,8 M
EV / Sales 2018 -
EV / Sales 2019 35 568 323x
Nbr of Employees -
Free-Float 59,6%
Chart UNIVO PHARMACEUTICALS LTD
Duration : Period :
Univo Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Golan Bitton Chief Executive Officer & Director
Moran Yossef Chief Financial Officer
Chaim Hurvitz Chairman
Ilana Lavon Chief Scientific Officer
Omer Layani Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
UNIVO PHARMACEUTICALS LTD-18.66%21
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298